Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
23 oct. 2024 09h15 HE
|
Cyclacel
NEW CLINICAL DATA FROM ONGOING, PHASE 2 STUDY OF ORAL FADRACICLIB AT THE 2024 ENA SYMPOSIUM.
Patients preselected for CDKN2A and/or CDKN2B abnormalities
Cyclacel Pharmaceuticals Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib’s Potential as a Precision Medicine for Cancer
03 juin 2024 08h00 HE
|
Cyclacel
CYCLACEL PHARMACEUTICALS REPORTS NEW CLINICAL DATA AT 2024 ASCO ANNUAL MEETING HIGHLIGHTING ORAL FADRACICLIB’S POTENTIAL AS A PRECISION MEDICINE FOR CANCER
The Sovini Group continues their Data Journey with Simpson Associates as their Fabric Partner
02 mai 2024 08h30 HE
|
Simpson Associates
Simpson Associates announces a partnership with The Sovini Group to implement Microsoft’s Fabric Platform, starting with our Proof of Concept.
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
19 mars 2024 16h05 HE
|
Cyclacel
– On Track to Start Oral Fadraciclib Phase 2 Proof of Concept in 1H 2024 – – Expect to Report Final Data from Fadraciclib 065-101 Dose Escalation – – Oral Plogosertib Preclinical Data Support...
Assosia and Simpson Associates Team Up to Unlock Product Matching Potential with Machine Learning
08 févr. 2024 04h57 HE
|
Simpson Associates
Read our Press Release on how Simpson Associates have teamed up with Assosia to precisely product match using Machine Learning.
Synlogic Announces Achievement of Proof of Concept for SYNB8802 in Enteric Hyperoxaluria Based on Urinary Oxalate Lowering in Phase 1b Study
15 déc. 2022 06h59 HE
|
Synlogic, Inc.
Results include -38% reduction in urinary oxalate compared to placebo in Roux-en-Y gastric bypass patients Favorable safety and tolerability, with frequency and severity of adverse events similar...
Medaro Spodumene Processing Technology Produces High-Purity Lithium Carbonate
10 févr. 2022 07h00 HE
|
Medaro Mining Corp.
—Readily formed Li2CO3 is 99.91% pure VANCOUVER, British Columbia, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Medaro Mining Corp. (CSE: MEDA) (OTC: MEDAF) (FWB: 1ZY) (“Medaro” or the “Company”), a...
Medaro Hard Rock Lithium Extraction Process Achieves Proof of Concept
13 janv. 2022 07h00 HE
|
Medaro Mining Corp.
VANCOUVER, British Columbia, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Medaro Mining Corp. (CSE: MEDA) (OTC: MEDAF) (FWB: 1ZY) (“Medaro” or the “Company”), a multi-faceted mineral explorer and joint venture...
ViGeneron signs global collaboration agreement for ophthalmic gene therapy development
05 janv. 2021 02h00 HE
|
ViGeneron GmbH
Collaboration with Biogen to develop gene therapy for an undisclosed target to treat inherited eye disease, plus option for additional targetThe companies will use ViGeneron’s proprietary vgAAV...
Standard Lithium Successfully Completes Proof-of-Concept of Modern Lithium Extraction and Crystallisation Technology and Makes Better Than Battery Quality Lithium Carbonate
03 déc. 2020 08h00 HE
|
Standard Lithium
HIGHLIGHTS >99.9% purity lithium carbonate produced (aka ‘3 nines’)Successful proof-of-concept of modern lithium processing technologyStart-to-finish direct extraction of lithium from brine in...